# Comparing the Three Analgesic Approaches

> **Educational work by a pre-medical student — not medical advice.** Not a clinical protocol, prescription, or patient handout, and not for patient care. See [DISCLAIMER](../DISCLAIMER.md).

### Post-mastectomy breast implant revision — educational dosing reference, November 2026

## How to read this comparison
This is a side-by-side summary of [Approach 1](Protocol_1_OFIA_With_PECS_Block.md), [Approach 2](Protocol_2_OFIA_BlockFree.md) and [Approach 3](Protocol_3_OpioidBased_NoBlocks.md). Numeric values are tagged to [DOSING_SOURCES.md](../DOSING_SOURCES.md) and are illustrative. **No universal first-, second- or third-line order is supported.** The numbering is for reference only. Selection is individual: procedure, comorbidities, contraindications and patient preference.

*Values changed from v2.0, and v2.0 values removed for lack of an acceptable source, are listed in [RELEASE_NOTES.md](../RELEASE_NOTES.md).*

---

## Abbreviations
OFA, opioid-free anesthesia; PECS, pectoral nerve blocks; PONV, postoperative nausea and vomiting; LAST, local anesthetic systemic toxicity; MME, morphine milligram equivalents (oral); OSA, obstructive sleep apnea; TOFR, train-of-four ratio; IBW, ideal body weight.

---

## Questions to ask of any study before applying it

| Domain | Question |
|---|---|
| Population | Augmentation, oncologic surgery, implant revision or autologous reconstruction? |
| Intervention | Which drugs, blocks, infiltration and rescue were actually used? |
| Comparator | Was background multimodal care comparable? |
| Outcomes | Pain, opioid exposure, nausea, respiratory events, hemodynamics, function? |
| Harms | Were adverse events defined and actively collected? |
| Applicability | Does the evidence apply to implant revision? |

---

## Side-by-side features

| Feature | Approach 1: block + GA | Approach 2: GA, no block | Approach 3: opioid-inclusive GA |
|---|---|---|---|
| Regional anesthesia | PECS I+II or serratus | None (surgeon infiltration usual) | None (infiltration helpful) |
| Intra-op opioids | None planned; small rescue acceptable | None planned; small rescue acceptable | Fentanyl ± hydromorphone, individualized [S18](../DOSING_SOURCES.md#s18), [S19](../DOSING_SOURCES.md#s19) |
| Local-anesthetic toxicity concern | **Yes** (block ± infiltration) | **Yes** (infiltration) | **Yes** if infiltration is used |
| 20% lipid emulsion | Immediately available [S3](../DOSING_SOURCES.md#s3) | Immediately available [S3](../DOSING_SOURCES.md#s3) | Immediately available if infiltration [S3](../DOSING_SOURCES.md#s3) |
| IV lidocaine | **Not used** with blocks [S1](../DOSING_SOURCES.md#s1) | Not combined with infiltration [S1](../DOSING_SOURCES.md#s1) | Not combined with infiltration [S1](../DOSING_SOURCES.md#s1) |
| Main safety concerns | LAST; dexmedetomidine bradycardia/hypotension [S14](../DOSING_SOURCES.md#s14); ketamine sympathomimetic effects [S15](../DOSING_SOURCES.md#s15) | Same, plus sedative stacking | Opioid respiratory depression; PONV |
| PONV prophylaxis | By Apfel factors [S9](../DOSING_SOURCES.md#s9): two interventions for 1–2, three to four for ≥3 [S7](../DOSING_SOURCES.md#s7), [S8](../DOSING_SOURCES.md#s8) | Same | Same; postoperative opioids add one Apfel factor [S9](../DOSING_SOURCES.md#s9) |
| Reversal | Quantitative TOFR ≥0.9 [S10](../DOSING_SOURCES.md#s10); sugammadex by depth [S11](../DOSING_SOURCES.md#s11); neostigmine only at minimal depth [S10](../DOSING_SOURCES.md#s10), [S12](../DOSING_SOURCES.md#s12) | Same | Same |

*Removed from v2.0 (no acceptable source):*
- the "First-/Second-/Third-line" labels;
- "lowest / low / higher PONV" rankings;
- "very smooth / slower" emergence ratings;
- "best for" lists that implied superiority;
- PACU vital-sign frequencies, SpO₂-monitoring durations and RASS intervals per approach.

---

## Adjunct dose summary (label or consensus values)

| Agent | Value | Approaches | Source |
|---|---|---|---|
| Dexmedetomidine (off-label as GA adjunct) | Label procedural-sedation reference: load 1 mcg/kg over 10 min; maintenance 0.2–1 mcg/kg/h. >65 y: load 0.5 mcg/kg, reduce maintenance. Reduce in hepatic impairment | 1, 2; optional 3 | [S14](../DOSING_SOURCES.md#s14) |
| Ketamine (subanesthetic; off-label analgesic use) | Bolus ≤0.35 mg/kg; infusion up to ~1 mg/kg/h | 1, 2; optional 3 | [S15](../DOSING_SOURCES.md#s15) |
| IV lidocaine | ≤1.5 mg/kg IBW load over ~10 min; ≤1.5 mg/kg/h IBW; ≤120 mg/h; ≤24 h; not under 40 kg; **not concurrent with blocks or infiltration**, with ~4 h separation | Rarely applicable (only with no other local-anesthetic intervention) | [S1](../DOSING_SOURCES.md#s1) |
| Propofol | Induction ~2–2.5 mg/kg (<55 y) or ~1–1.5 mg/kg (elderly, debilitated, ASA III–IV). Maintenance 100–200 or 50–100 mcg/kg/min | All | [S16](../DOSING_SOURCES.md#s16) |
| Rocuronium | 0.6 mg/kg; RSI 0.6–1.2 mg/kg | All | [S17](../DOSING_SOURCES.md#s17) |
| Fentanyl | Individualized; label low-dose tier 2 mcg/kg; reduce in elderly or debilitated patients | 3 (rescue in 1–2) | [S18](../DOSING_SOURCES.md#s18) |
| Hydromorphone | 0.2–1 mg IV slowly; label interval every 2–3 h; lower start in elderly; ¼–½ in hepatic or renal impairment | 3 (rescue in 1–2) | [S19](../DOSING_SOURCES.md#s19) |
| Sugammadex | 2 mg/kg (T2 reappeared); 4 mg/kg (1–2 post-tetanic counts) | All | [S11](../DOSING_SOURCES.md#s11) |
| Neostigmine + glycopyrrolate | 0.03–0.07 mg/kg (max 0.07 mg/kg or 5 mg) at minimal depth only; glycopyrrolate 0.2 mg per 1 mg neostigmine | All | [S10](../DOSING_SOURCES.md#s10), [S12](../DOSING_SOURCES.md#s12), [S13](../DOSING_SOURCES.md#s13) |

---

## What the cited evidence supports (directional)

| Outcome | Direction | Author's certainty judgment |
|---|---|---|
| Early pain and 24-h opioid use | Lower with PECS/serratus block vs no block (meta-analyses in [06](../06_References_Evidence_Breast_Augmentation.md)) | Moderate |
| PONV | Lower with opioid-sparing techniques and TIVA; reduced by multimodal prophylaxis [S7](../DOSING_SOURCES.md#s7), [S8](../DOSING_SOURCES.md#s8) | Moderate |
| Hypoxemia / bradycardia | **Higher** with dexmedetomidine-based OFA vs opioid-based (POFA RCT) | Moderate (single large RCT) |
| PACU duration, satisfaction, admission | No direct comparative data for implant revision | Very low / none |

---

## Selection considerations (not a decision rule)

| Situation | Considerations |
|---|---|
| Block feasible and accepted | Approach 1 offers block-related early analgesia; weigh block risks and the shared local-anesthetic budget [S4](../DOSING_SOURCES.md#s4), [S5](../DOSING_SOURCES.md#s5) |
| Needle aversion, block contraindicated or declined | Approach 2 or 3. Infiltration quality matters; IV lidocaine is not combined with infiltration [S1](../DOSING_SOURCES.md#s1) |
| Antithrombotic therapy | Superficial plane blocks may be acceptable. Decide by agent, dose, timing and block depth [S36](../DOSING_SOURCES.md#s36) |
| High PONV risk (Apfel ≥3) | Three to four prophylactic interventions under **any** approach [S7](../DOSING_SOURCES.md#s7); opioid sparing and TIVA reduce baseline risk [S8](../DOSING_SOURCES.md#s8) |
| OSA (STOP-Bang 5–8 high risk [S33](../DOSING_SOURCES.md#s33)) | Minimize sedatives and opioids under any approach; enhanced monitoring per policy |
| Long-term opioid therapy | Block + multimodal care is reasonable; continue the baseline regimen; do not abruptly discontinue [S21](../DOSING_SOURCES.md#s21) |
| Opioid use disorder | Continue the medication for OUD; do not withhold indicated opioids |
| Contraindications to the opioid-sparing adjuncts, or patient preference | Approach 3 with opioid stewardship and monitoring |

---

*Evidence: [06](../06_References_Evidence_Breast_Augmentation.md). Dose sources: [DOSING_SOURCES.md](../DOSING_SOURCES.md). Author: Collin B. George, pre-medical student. License: CC BY 4.0. Educational framework; not clinically validated; not for patient care.*